1 / 3

Decontamination Sector Report - September 2010 Overview and Market Insights

The September 2010 Decontamination Sector Report provides an in-depth analysis of the market landscape, highlighting the distribution of company sizes, with 40% classified as large, 20% as medium, and 40% as small businesses. The report also notes a significant drop in the response rate from sector members to below 50% for the first time. Key insights include member concerns about funding shifts towards vaccines instead of surface decontamination technologies, and challenges regarding the justifiability of R&D investments in military technologies due to budget cuts and delays.

rea
Télécharger la présentation

Decontamination Sector Report - September 2010 Overview and Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Decontamination Sector ReportSeptember 10, 2010

  2. Decontamination Sector Profile • 12 Active Companies • Company Size • 40% Large Businesses • 20% Medium Businesses • 40% Small Businesses • APBI participation was close to 60% • 1st time that response rate from sector fell below 50%

  3. Decontamination Sector – CBDAIFGeneral Comments from Sector Members MEMBER COMMENTS • Surprise was registered that with Mr. Reed’s departure and the expected increase in funding of Chem-Bio, that funds were being shifted toward vaccines. • R&D is already difficult to justify for Military-only technologies. Budget cuts, delays in appropriations, and shift toward medical countermeasures makes investment in Surface Decontamination hard to justify. MEMBER QUESTIONS • In light of recent attempts to streamline or reduce number of products on Dept of State ITAR list are there JPM Decon products that could be moved off ITAR list ? • How will shift to BioSurveillance and vaccines impact Decon sector? • Is there a restructuring plan for JPM Decon?

More Related